Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
$0.89
-$0.05(-2.48%)
At close: 4:00 PM EST
$0.89
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$0.52 - $3.01
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$86.47M
Enterprise Value$74.93M
Total Cash (Recent Filing)$167.59M
Total Debt (Recent Filing)$17.66M
Price to Earnings (P/E)―
Beta3.82
Next Earnings
Mar 12, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding84,774,180
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.17
Price to Sales (P/S)2.28
P/FCF Ratio-0.73
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit0.71
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$2.20Price Target Upside147.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform InnovationSTRO aims to leverage their proprietary cell-free ADC manufacturing platform to optimize ADC components for improved clinical profiles.
Regulatory ProgressThe FDA has cleared the IND for STRO-004 and the company aims to dose the first patient in the Phase I.
Therapeutic AdvancementsSTRO-004 is viewed as having a best-in-class profile based on preclinical data demonstrating superior anti-tumor activity and the ability to mitigate common adverse effects.
Bears Say
Clinical Strategy ConcernsThe expanded dataset raises questions about clinical execution, indication prioritization, and dosing strategy, particularly regarding how quickly the dose will approach the biologically active window.
Investment RisksSutro’s pipeline is still early, and the company is seen as a longer term opportunity for investors who are comfortable underwriting preclinical and early clinical risk.
Pipeline ChallengesThe decision to discontinue luvelta in PROC earlier this year impacts the company's pipeline.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $0.52 and its highest was $3.01 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $86.47M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 12, 2026 which is in 104 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 06, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.394 by -$0.276.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -0.44.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 84,774,180 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.394. Following the earnings report the stock price went down -12.766%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
Sutro Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.20 (147.19% Upside)
$2.20 (147.19% Upside)
Insider Transactions
Bought Shares
Worth $79.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
-1810.01%
Trailing 12-Months
Asset Growth
-46.35%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$2.20
▲(147.19% Upside)
Technical Analysis
Ownership Overview
1.44% Insiders
5.74% Mutual Funds
4.83% Other Institutional Investors
83.17% Public Companies and
Individual Investors